{"id":"W2792937256","doi":"10.1056/nejmoa1712126","title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4643,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; University Hospital Foundation","funders":"Foundation Medicine; Kite Pharma; Genentech; Astellas Pharma; Eisai; Jounce Therapeutics; Takeda Oncology; Mirati Therapeutics; Acceleron; Clovis Oncology; BioMarin Pharmaceutical; Mylan; Celldex Therapeutics; Taiho Pharmaceutical; Horizon Pharma; Ipsen; Array BioPharma; Bayer HealthCare; Exelixis; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; INOVIO Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; LEO Pharma; Intuitive Surgical; Pfizer; EUSA Pharma; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ipilimumab; Sunitinib; Nivolumab; Renal cell carcinoma; Medicine; Internal medicine; Oncology; Cancer research; Urology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}